To establish a leadership position in the early diagnosis and treatment of ischemic injury (such as heart attack and stroke) and in Oncology patients by introducing Rockland Technimed's proprietary Oxy-17 technology.

Possibly increasing the window of opportunity for treating ischemic attack victims well beyond the currently acceptable "Golden Hours" of injury from the current 3 hours to possibly 12 hours as suggested by current research studies.

A means to guide and evaluate the efficiency of radiation treatment in cancer tissue.


Provide a consistent biomarker for drug discovery to define the drugs mechanism of action at the cellular level during screening, preclinical and clinical use with the potential to reduce the time and cost of drug discovery.

  • To bring Oxy-17 ® to global markets for healthcare and drug discovery applications.
  • Establish a strategic alliances with established marketing partners, in each of the major global geographic markets, and launch product sales.
  • Develop the latent global market sector of Oxygen Metabolism Imaging to $750-$950 million sales by the fifth year of product introduction.
  • Establish rapid high growth rates per year during the first ten years of this operation


What the press says :

Rockland Technimed Ltd.
Maratha House, 3 Larissa Court, Airmont, NY USA
Telephone: 001-(845)-426-3406, Fax -001- (845)-426-1109
Email - info@technimed.com Webmaster - webmaster@technimed.com
Copyright © 1999-2007 Rockland Technimed Ltd. All rights reserved.
Oxy-17® is a registered Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, namely, contrast media for medical imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of contrast media for use in In-Vivo imaging.